March 2007 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

March 2007

Pharmaceutical Technology


REGULATIONS/BIOLOGICS

FDA Proposes Additional Information to Current Biologics Reporting Form



Rockville, MD (Jan. 30)—The US Food and Drug Administration's ( http://www.fda. gov/) Center for Biologics Evaluation and Research (CBER) is proposing an addendum to its current biologics reporting form to better classify potential recalls.

FDA must submit such a request to the Office of Management and Budget (Washington, DC, http://www.whitehouse.gov/omb/) for approval but first open the request for a 30-day public-comment period. Notice of the request was published in the Jan. 30, 2007 issue of the Federal Register (1).

Specifically, CBER is developing an addendum to Form FDA 3486, the form now used to report biological product deviations (BPDs). The Web-based addendum (Form FDA 3486A) would request additional information when a BPD report has been reviewed by FDA and evaluated as a possible recall. The additional information would include information not contained in Form 3486 such as distribution pattern, method of consignee notification, consignee(s) of products for further manufacture, additional product information, and updated product disposition.

This information would be requested by CBER via e-mail to the submitter of the BPD report and would be used by CBER for recall classification.

The new form, Form FDA 3486A, would be used only for biological products regulated by CBER and not biological products regulated by the Center for Drug Evaluation and Research.

CBER estimates that 5% of the total BPD reports submitted to CBER would need additional information submitted in the addendum. It estimates that it would take between 15 and 45 minutes to complete the addendum. Activities such as investigating, changing standard operating procedures or processes, and follow-up are not included in the calculation of time for the report.

Reference

1. US Food and Drug Administration, "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Biological Products; Reporting of Biological Product Deviations in Manufacturing; Forms FDA 3486 and 3486A," Federal Register 72 (19), 4267–4269 (Jan. 30, 2007, Docket No. 2006N-0421), http://frwebgate1.access.gpo.gov/cgi-bin/waisgate.cgi?WAISdocID=279262421529+0+0+0&WAISaction=retrieve/, accessed Jan. 31, 2007.

-Patricia Van Arnum

MANUFACTURING

Pfizer Wins Court Battle Over Manufacturing Process for Norvasc

New York, NY (Jan. 31)—Pfizer, Inc. ( http://www.pfizer.com/) scored a victory over Synthon IP (Gainesville, VA, http://www.synthonip.com/) in a patent infringement lawsuit over the manufacturing process for "Norvasc" (amlodipine). Norvasc is one of Pfizer's top-selling drugs with 2006 sales of $1.3 billion.

According to Pfizer, the federal district court in the Eastern District of Virginia (Alexandria) ruled that Synthon obtained, by inequitable conduct, two US patents that covered a process and an intermediate compound used to make the active ingredient in Pfizer's Norvasc.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here